The illusion of polygenic disease risk prediction.
paper
Cited
Public
Unavailable
- Authors
- Wald, Nicholas J; Old, Robert
- Year
- 2019
- Journal
- Genetics in medicine : official journal of the American College of Medical Genetics
- PMID
- 30635622
- DOI
- 10.1038/s41436-018-0418-5
A problem at the interface of genomic medicine and medical screening is that genetic associations of etiological significance are often interpreted as having predictive significance. Genome-wide association studies (GWAS) have identified many thousands of associations between common DNA variants and hundreds of diseases and benign traits. This knowledge has generated many publications with the understandable expectation that it can be used to derive polygenic risk scores for predicting disease to identify those at sufficiently high risk to benefit from preventive intervention. However, the expectation rests on the incorrect assumption that odds ratios derived from polygenic risk scores that are important etiologically are also directly useful in risk prediction and population screening.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Using polygenic scores for identifying individuals at increased risk of substance use disorders in clinical and population samples. | 2020 | 32555147 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| 'Everyday genetics' in the Mass Observation Project: insights on genetics from people writing for an archive of everyday life in Britain. | Horton R et al. | — | 2026 | → |
| Assessment of the value of polygenic risk scores in the prevention of disease. | Hingorani AD | — | 2025 | → |
| Defining next steps in the clinical implementation of polygenic scores: A landscape analysis of professional groups' perspectives. | Purvis R et al. | — | 2025 | → |
| "DNA tests for every baby on the NHS". | Wald NJ et al. | — | 2025 | → |
| Genomic prediction with kinship-based multiple kernel learning produces hypothesis on the underlying inheritance mechanisms of phenotypic traits. | Raimondi D et al. | — | 2025 | → |
| Low Stability and Specificity of Polygenic Risk Scores for Major Psychiatric Disorders Limit Their Clinical Utility. | Mollon J et al. | — | 2025 | → |
| Multiomics in atherosclerotic cardiovascular disease. | Nordestgaard LT et al. | — | 2025 | → |
| Personalization of primary prevention: Exploring the role of coronary artery calcium and polygenic risk score in cardiovascular diseases. | Mekhael M et al. | — | 2025 | → |
| Polygenic risk score prediction accuracy convergence. | Henches L et al. | — | 2025 | → |
| Promises and pitfalls of preimplantation genetic testing for polygenic disorders: a narrative review. | Roura-Monllor JA et al. | — | 2025 | → |
| Adopting Mechanistic Molecular Biology Approaches in Exposome Research for Causal Understanding. | Foreman AL et al. | — | 2024 | → |
| Association of retinal optical coherence tomography metrics and polygenic risk scores with cognitive function and future cognitive decline. | Sekimitsu S et al. | — | 2024 | → |
| Biologically meaningful genome interpretation models to address data underdetermination for the leaf and seed ionome prediction in Arabidopsis thaliana. | Raimondi D et al. | — | 2024 | → |
| Characterizing the Relationship between Expression Quantitative Trait Loci (eQTLs), DNA Methylation Quantitative Trait Loci (mQTLs), and Breast Cancer Risk Variants. | Ho PJ et al. | — | 2024 | → |
| Clinical associations with a polygenic predisposition to benign lower white blood cell counts. | Mosley JD et al. | — | 2024 | → |
| Enhancing prediction accuracy of coronary artery disease through machine learning-driven genomic variant selection. | Alireza Z et al. | — | 2024 | → |
| Evaluating the cost-effectiveness of polygenic risk score-stratified screening for abdominal aortic aneurysm. | Kelemen M et al. | — | 2024 | → |
| Parkinson's Disease is Predominantly a Genetic Disease. | Lim SY et al. | — | 2024 | → |
| Polygenic Risk Scores in Predicting Coronary Artery Disease in Symptomatic Patients. A Validation Study. | Kujala I et al. | — | 2024 | → |
| Preimplantation Genetic Testing for Polygenetic Conditions: A Legal, Ethical, and Scientific Challenge. | Ginod P et al. | — | 2024 | → |
| Screening embryos for polygenic disease risk: a review of epidemiological, clinical, and ethical considerations. | Capalbo A et al. | — | 2024 | → |
| Two-Stage Whole-Exome Sequencing Improves to Predict a Risk of Adult Moyamoya Disease in 369,570 Individuals | Hong EP et al. | — | 2024 | — |
| Weighty matters: Considering the ethics of genetic risk scores for obesity. | Houtz C | — | 2024 | → |
| A polygenic risk score to help discriminate primary adrenal insufficiency of different etiologies. | Aranda-Guillén M et al. | — | 2023 | → |
| A polygenic score for reduced kidney function and adverse outcomes in a cohort with chronic kidney disease. | Steinbrenner I et al. | — | 2023 | → |
| Clinical utility of polygenic risk scores: a critical 2023 appraisal. | Koch S et al. | — | 2023 | → |
| Combining genetic and non-genetic risk factors to predict disease, and reporting the screening performance of risk models. | Old R | — | 2023 | → |
| Could interventions on physical activity mitigate genomic liability for obesity? Applying the health disparity framework in genetically informed studies. | Herle M et al. | — | 2023 | → |
| COVID-19 host genetics and ABO blood group susceptibility. | Ellinghaus D | — | 2023 | → |
| Direct-to-consumer genetic tests providing health risk information: A systematic review of consequences for consumers and health services. | Nolan JJ et al. | — | 2023 | → |
| Ethical Considerations in Research with Genomic Data. | Horton R et al. | — | 2023 | → |
| Ethical layering in AI-driven polygenic risk scores-New complexities, new challenges. | Fritzsche MC et al. | — | 2023 | → |
| Ethical, legal, and social implications of genetic risk prediction for multifactorial disease: a narrative review identifying concerns about interpretation and use of polygenic scores. | Chapman CR | — | 2023 | → |
| Evaluation of optimal methods and ancestries for calculating polygenic risk scores in East Asian population. | Kim DJ et al. | — | 2023 | → |
| Genome interpretation in a federated learning context allows the multi-center exome-based risk prediction of Crohn's disease patients. | Raimondi D et al. | — | 2023 | → |
| Human Genetics Society of Australasia Position Statement: Use of Polygenic Scores in Clinical Practice and Population Health. | Young MA et al. | — | 2023 | → |
| Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). | Hanson H et al. | — | 2023 | → |
| Performance of polygenic risk scores in screening, prediction, and risk stratification: secondary analysis of data in the Polygenic Score Catalog. | Hingorani AD et al. | — | 2023 | → |
| Realistic expectations are key to realising the benefits of polygenic scores. | Sud A et al. | — | 2023 | → |
| The clinical application of polygenic risk scores: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG). | Abu-El-Haija A et al. | — | 2023 | → |
| An opportunity for primary prevention research in psychotic disorders. | Gershon ES et al. | — | 2022 | → |
| A Smoothed Version of the Lassosum Penalty for Fitting Integrated Risk Models Using Summary Statistics or Individual-Level Data. | Hahn G et al. | — | 2022 | → |
| Blood gene expression risk profiles and interstitial lung abnormalities: COPDGene and ECLIPSE cohort studies. | Moll M et al. | — | 2022 | → |
| Clinical genomics and precision medicine. | Pena SDJ et al. | — | 2022 | → |
| Commentary: Polygenic risk for breast cancer: in search for potential clinical utility. | Wang T et al. | — | 2022 | → |
| Concerns about the use of polygenic embryo screening for psychiatric and cognitive traits. | Lencz T et al. | — | 2022 | → |
| Contribution of a genetic risk score to ethnic differences in fatty liver disease. | Kubiliun MJ et al. | — | 2022 | → |
| Do we measure or compute polygenic risk scores? Why language matters. | Penders B et al. | — | 2022 | → |
| Editorial: Towards genome interpretation: Computational methods to model the genotype-phenotype relationship. | Raimondi D et al. | — | 2022 | → |
| From genotype to phenotype in Arabidopsis thaliana: in-silico genome interpretation predicts 288 phenotypes from sequencing data. | Raimondi D et al. | — | 2022 | → |
| Genomics and justice: mitigating the potential harms and inequities that arise from the implementation of genomics in medicine. | Clarke AJ et al. | — | 2022 | → |
| Heritability: What's the point? What is it not for? A human genetics perspective. | Robette N et al. | — | 2022 | → |
| Identification of hub genes and transcription factor regulatory network for heart failure using RNA-seq data and robust rank aggregation analysis. | Tu D et al. | — | 2022 | → |
| Including APOL1 alleles and ancestry adjustments improve a genome-wide polygenic CKD score. | Yu Z et al. | — | 2022 | → |
| Incremental Value of Polygenic Risk Scores in Primary Prevention of Coronary Heart Disease: A Review. | Groenendyk JW et al. | — | 2022 | → |
| Polygenic risk provides biological validity for the ICHD-3 criteria among Finnish migraine families. | Häppölä P et al. | — | 2022 | → |
| Polygenic risk score for embryo selection-not ready for prime time. | Polyakov A et al. | — | 2022 | → |
| Polygenic risk scores to stratify cancer screening should predict mortality not incidence. | Vickers AJ et al. | — | 2022 | → |
| PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients. | Giardiello D et al. | — | 2022 | → |
| Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. | Hurson AN et al. | — | 2022 | → |
| Stability of polygenic scores across discovery genome-wide association studies. | Schultz LM et al. | — | 2022 | → |
| The False Dawn of Polygenic Risk Scores for Human Disease Prediction. | Herzig AF et al. | — | 2022 | → |
| The Genetic contribution to solving the cocktail-party problem. | Mathias SR et al. | — | 2022 | → |
| The genetic risk of gestational diabetes in South Asian women. | Lamri A et al. | — | 2022 | → |
| The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice. | Forzano F et al. | — | 2022 | → |
| Body Mass Index and Birth Weight Improve Polygenic Risk Score for Type 2 Diabetes. | Moldovan A et al. | — | 2021 | → |
| Dynamic change in the association of a cigarettes-per-day polygenic risk score across the numeric range of its corresponding phenotype over adolescence and young adulthood. | Deutsch AR et al. | — | 2021 | → |
| Low Back Pain With Persistent Radiculopathy; the Clinical Role of Genetic Variants in the Genes SOX5, CCDC26/GSDMC and DCC. | Lie MU et al. | — | 2021 | → |
| Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis. | Placek K et al. | — | 2021 | → |
| May direct-to-consumer genetic testing have an impact on general practitioners' daily practice? a cross-sectional study of patients' intentions towards this approach. | Cohidon C et al. | — | 2021 | → |
| Médecine personnalisée et prévention des maladies chroniques : l’attitude des médecins généralistes. | Cardinaux R et al. | — | 2021 | → |
| Polygenic risk scores across the extended psychosis spectrum. | Smigielski L et al. | — | 2021 | → |
| Polygenic risk scores in the clinic: new perspectives needed on familiar ethical issues. | Lewis ACF et al. | — | 2021 | → |
| Statistical Learning Methods Applicable to Genome-Wide Association Studies on Unbalanced Case-Control Disease Data. | Dai X et al. | — | 2021 | → |
| The clinical utility of polygenic risk scores for chronic lymphocytic leukemia. | Sud A et al. | — | 2021 | → |
| The Genetic Basis of Vitiligo. | Spritz RA et al. | — | 2021 | → |
| The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. | Orringer CE et al. | — | 2021 | → |
| Utility of polygenic embryo screening for disease depends on the selection strategy. | Lencz T et al. | — | 2021 | → |
| Validity and Prognostic Value of a Polygenic Risk Score for Parkinson's Disease. | Koch S et al. | — | 2021 | → |
| Will polygenic risk scores for cancer ever be clinically useful? | Sud A et al. | — | 2021 | → |
| An Outbreak of Polygenic Scores for Coronary Artery Disease. | Rotter JI et al. | — | 2020 | → |
| Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts. | Moll M et al. | — | 2020 | → |
| Combined Utility of 25 Disease and Risk Factor Polygenic Risk Scores for Stratifying Risk of All-Cause Mortality. | Meisner A et al. | — | 2020 | → |
| Harveian Oration 2019: Prediction and prevention in the genomic era. | Burn J | — | 2020 | → |
| Parkinson's disease determinants, prediction and gene-environment interactions in the UK Biobank. | Jacobs BM et al. | — | 2020 | → |
| Polygenic risk scores and the prediction of common diseases. | Ala-Korpela M et al. | — | 2020 | → |
| Polygenic Risk Scores in Coronary Artery Disease and Atrial Fibrillation. | Gladding PA et al. | — | 2020 | → |
| Predictive Accuracy of a Polygenic Risk Score Compared With a Clinical Risk Score for Incident Coronary Heart Disease. | Mosley JD et al. | — | 2020 | → |
| The challenges of maintaining genetic privacy. | Carmi S | — | 2020 | → |
| The genetic architecture of vitiligo. | Roberts GHL et al. | — | 2020 | → |
| Using polygenic scores for identifying individuals at increased risk of substance use disorders in clinical and population samples. | Barr PB et al. | — | 2020 | → |
| Consent and Autonomy in the Genomics Era. | Horton R et al. | — | 2019 | → |
| Direct-to-consumer genetic testing. | Horton R et al. | — | 2019 | → |
| Does big data require a methodological change in medical research? | Caliebe A et al. | — | 2019 | → |
| Family Clustering of Autoimmune Vitiligo Results Principally from Polygenic Inheritance of Common Risk Alleles. | Roberts GHL et al. | — | 2019 | → |
| Opportunities and Challenges in Interpreting and Sharing Personal Genomes. | Rubin IR et al. | — | 2019 | → |
| Quantifying the polygenic contribution to variable expressivity in eleven rare genetic disorders. | Oetjens MT et al. | — | 2019 | → |
| Validation of Genome-Wide Polygenic Risk Scores for Coronary Artery Disease in French Canadians. | Wünnemann F et al. | — | 2019 | → |